Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).

ABSTRACT:

Importance

Due to the emergence of highly transmissible SARS-CoV-2 variants, evaluation of boosters is needed.

Objectives

Evaluate safety and immunogenicity of 100-μg of mRNA-1273 booster dose in adults.

Design

Open-label, Phase 2/3 study.

Setting

Multicenter study at 8 sites in the U.S.

Participants

The mRNA-1273 100-μg booster was administered to adults who previously received a two dose primary series of 100-μg mRNA-1273 in the phase 3 Coronavirus Efficacy (COVE) trial, at least 6 months earlier.

Intervention

Lipid nanoparticle containing 100-μg of mRNA encoding the spike glycoprotein of SARS-CoV-2 (Wuhan-HU-1).

Main outcomes and measures

Solicited local and systemic adverse reactions, and unsolicited adverse events were collected after

SUBMITTER: Chalkias S 

PROVIDER: S-EPMC8923111 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature